News: Simtuzumab

We provide the latest news and info on Simtuzumab


Bidness ETC

Gilead's simtuzumab fails pancreatic cancer trial
PharmaTimes
The company has announced results from a Phase II study evaluating simtuzumab, an inhibitor of the lysyl oxidase-like-2 enzyme, in combination with current standard of care gemcitabine (Eli Lilly's Gemzar). The data show that the addition of simtuzumab ...
Gilead Down on Weak Simtuzumab Data and Sovaldi NewsZacks.com
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...Business Wire (press release)
Gilead's simtuzumab fails Phase 2 trial (GILD)Seeking Alpha (registration)
StockWise Daily
all 45 news articles »

Published on Tuesday 24th of February 2015 10:08:29 AM Read more...


For advanced pancreatic cancer, simtuzumab not significantly more effective ...
Oncology Nurse Advisor
Gilead Sciences, Inc. has announced results from their phase 2 trial studying simtuzumab plus gemcitabine for the treatment of patients with previously untreated advanced pancreatic cancer. Researchers found that patients who received gemcitabine in ...

Published on Tuesday 24th of February 2015 10:08:29 AM Read more...


HCV Stocks Struggle As Gilead, Merck Face Headwinds GILD MRK ABBV ACHN
Investor's Business Daily
"We believe this multiple is reasonable as it is in line with comparable low-growth, large-cap pharma and also reflects the lack of visibility on long-term trajectory of its HCV franchise as well as pipeline opportunities such as Simtuzumab antibody ...

and more »

Published on Tuesday 24th of February 2015 10:08:29 AM Read more...


Drug Discovery & Development

What Does Orphan Drug Approval For Gilead Sciences, Inc. (GILD)'s ...
InvestCorrectly
Gilead Sciences, Inc. (NASDAQ:GILD)'s monoclonal antibody Simtuzumab recently obtained orphan drug status as a treatment for a rare liver-related disorder – primary sclerosing cholangitis. The designation may provide Gilead increased patent protection ...
Gilead Sciences: A 'Logical' Deal That 'Fits Well'Barron's (blog)
Gilead Sciences Inc To Acquire Phenex's Liver-Disease ProgramBidness ETC
Gilead Sciences Just Received Orphan Drug Status For Liver TreatmentBenzinga

all 107 news articles »

Published on Tuesday 24th of February 2015 10:08:29 AM Read more...


Gilead Fundamentals Appear Better Than The Stock 'Is Suggesting' (GILD)
Seeking Alpha (registration)
I am particularly impressed with simtuzumab for fibrosis and GS-4997 for diabetic nephropathy. These represent huge unmet medical needs, and successful commercialization would provide for multi-billion dollar revenue opportunities. Importantly, Gilead ...

and more »

Published on Tuesday 24th of February 2015 10:08:29 AM Read more...


Comments On Gilead's Quarter And The Road Ahead
Seeking Alpha (registration)
Also, Gilead's antifibrotic pipeline product candidate simtuzumab failed in a Phase 2 in the bone marrow disease myelofibrosis. The company was asked about this in the Q&A and expressed confidence in simtuzumab's potential in such diseases as NASH ...

and more »

Published on Tuesday 24th of February 2015 10:08:29 AM Read more...


Gilead Sciences' (GILD) CEO John Martin on Q4 2014 Results - Earnings Call ...
Seeking Alpha (registration)
Simtuzumab the anti-LOXL2 antibody has been in evaluation for myelofibrosis, pancreatic cancer and colorectal cancer. In these three indications there was no evidence of efficacy although Simtuzumab was safe and well tolerated. Simtuzumab is undergoing ...

and more »

Published on Tuesday 24th of February 2015 10:08:29 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts